Inventage Lab (CEO Ju-Hee Kim) announced on the 19th that it has signed an agreement with Boehringer Ingelheim, a German multinational pharmaceutical company, to co-develop a long-acting injectable formulation for a new peptide drug.

Inventage Lab will develop a long-acting injectable formulation based on Boehringer Ingelheim's drug candidate and supply samples for preclinical trials. Following Boehringer Ingelheim's internal evaluation process, the two companies will collaborate on clinical development and enter into a global supply agreement for joint response to clinical development, clinical sample manufacturing, and commercialization. After the product launch, a separate agreement may be si